Systemic thromboembolic adverse events in patients treated with intravitreal anti-VEGF drugs for neovascular age-related macular degeneration

Expert Opinion on Biological Therapy

Volumn 12, Issue 10, 2012, Pages 1299-1313

  Costagliola, Ciro ^a   Agnifili, Luca ^b   Arcidiacono, Barbara ^c   Duse, Sarah ^c   Fasanella, Vincenzo ^b   Mastropasqua, Rodolfo ^d   Verolino, Marco ^a   Semeraro, Francesco ^c  

^a UNIVERSITY OF MOLISE   (Italy)

^b UNIVERSITY OF CHIETI   (Italy)

^c UNIVERSITY OF BRESCIA   (Italy)

^d UNIVERSITY OF VERONA   (Italy)

Author keywords

Aflibercept; Age related macular degeneration; Anti VEGF; Bevacizumab; Intravitreal administration; Pegaptanib; Ranibizumab; Systemic adverse events; Systemic side effects

Indexed keywords

AFLIBERCEPT; BEVACIZUMAB; PEGAPTANIB; RANIBIZUMAB; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN ANTIBODY; VEGF TRAP EYE;

CEREBROVASCULAR ACCIDENT; DEEP VEIN THROMBOSIS; DRUG APPROVAL; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG TOLERABILITY; HEART INFARCTION; HUMAN; HYPERTENSION; LUNG EMBOLISM; NONHUMAN; OFF LABEL DRUG USE; RECURRENT DISEASE; RETINA MACULA AGE RELATED DEGENERATION; REVIEW; STROKE; SUBRETINAL NEOVASCULARIZATION; THROMBOEMBOLISM; THROMBOPHLEBITIS; TRANSIENT ISCHEMIC ATTACK;

ADMINISTRATION, OPHTHALMIC; HUMANS; THROMBOEMBOLISM; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VITREOUS BODY; WET MACULAR DEGENERATION;

EID: 84866249108     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.2012.707176     Document Type: Review

References (121)

1. Klein R, Peto T, Bird A, et al. The epidemiology of age-related macular degeneration. Am J Ophthalmol 2004;137:486-95
2. Resnikoff S, Pascolini D, Etya'ale D, et al. Global data on visual impairment in the year 2002. Bull World Health Organ 2004;82:844-51
3. Friedman DS, O'Colmain BJ, Munoz B, et al. Eye Diseases Prevalence Research Group. Prevalence of age-related macular degeneration in the United States. Arch Ophthalmol 2004;22:64-572
4. Espinosa-Heidmann DG, Marin-Castano ME, Pereira-Simon S, et al. Gender and estrogen supplementation increases severity of experimental choroidal neovascularization. Exp Eye Res 2005;80:413-23
5. Klaver CC, Wolfs RC, Vingerling JR, et al. Age-specific prevalence and causes of blindness and visual impairment in an older population: The Rotterdam Study. Arch Ophthalmol 1998;116:653-8
6. Bressler NM, Bressler SB, Fine SL. Age-related macular degeneration. Surv Ophthalmol 1988;32:375-413
7. Roh MI, Kim HS, Song JH, et al. Concentration of cytokines in the aqueous humor of patients with naive, recurrent and regressed CNV associated with AMD after bevacizumab treatment. Retina 2009;29:523-9
8. Wormald R, Evans J, Smeeth L, et al. Photodynamic therapy for neovascular age-related macular degeneration. Cochrane Database Syst Rev 2007;3
9. Vedula SS, Krzystolik M. Antiangiogenic therapy with anti-vascular endothelial growth factor modalities for neovascular age-related macular degeneration. Cochrane Database Syst Rev 2008;2
10. Ohr M, Kaiser PK. Intravitreal aflibercept injection for neovascular (wet) age-related macular degeneration. Expert Opin Pharmacother 2012;13:585-91
11. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2004;9:69-76
12. Senger DR, Galli SJ, Dvorak AM, et al. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 1983;219:983-5
13. Ferrara N, Henzel WJ. Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem Biophys Res Commun 1981;161:851-8
14. Takahashi H, Shibuya M. The vascular endothelial growth factor (VEGF)/VEGF receptor system and its role under physiological and pathological conditions. Clin Sci (Lond) 2005;109:227-41
15. Park JE, Keller GA, Ferrara N. The vascular endothelial growth factor isoforms (VEGF): Differential deposition into the subepithelial extracellular matrix and bioactivity of extracellular matrix-bound VEGF. Mol Biol Cell 1993;4:1317-26
16. Lee S, Jilani SM, Nikolova GV, et al. Processing of VEGF-A by matrix metalloproteinases regulates bioavailability and vascular patterning in tumors. J Cell Biol 2005;169:681-91
17. Pepper MS. Extracellular proteolysis and angiogenesis. Thromb Haemost 2001;86:346-55
18. Olofsson B, Korpelainen E, Pepper MS, et al. Vascular endothelial growth factor B (VEGF-B) binds to VEGF receptor-1 and regulates plasminogen activator activity in endothelial cells. Proc Natl Acad Sci USA 1998;95:11709-14
19. Carmeliet P, Ferreira V, Breier G, et al. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature 1996;380:435-9
20. Shibuya M, Yamaguchi S, Yamane A, et al. Nucleotide sequence and expression of a novel human receptor-type tyrosine kinase gene (flt) closely related to the fms family. Oncogene 1990;5:519-24
21. Park JE, Chen HH, Winer J, et al. Placenta growth factor. Potentiation of vascular endothelial growth factor bioactivity, in vitro and in vivo, and high affinity binding to Flt-1 but not to Flk-1/KDR. J Biol Chem 1994;269:25646-54
22. Ferrara N. Vascular endothelial growth factor: Basic science and clinical progress. Endocr Rev 2004;25:581-611
23. Leung DW, Cachianes G, Kuang WJ, et al. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 1989;246:1306-9
24. Connolly DT, Heuvelman DM, Nelson R, et al. Tumor vascular permeability factor stimulates endothelial cell growth and angiogenesis. J Clin Invest 1989;84(5):1470-8
25. Martin AC, Thornton JD, Liu J, et al. Pathogenesis of persistent hyperplastic primary vitreous in mice lacking the arf tumor suppressor gene. Invest Ophthalmol Vis Sci 2004;45:3387-96
26. Marneros AG, Fan J, Yokoyama Y, et al. Vascular endothelial growth factor expression in the retinal pigment epithelium is essential for choriocapillaris development and visual function. Am J Pathol 2005;167:1451-9
27. Stone J, Itin A, Alon T, et al. Development of retinal vasculature is mediated by hypoxia-induced vascular endothelial growth factor (VEGF) expression by neuroglia. J Neurosci 1995;15:4738-47
28. Gerhardt H, Golding M, Fruttiger M, et al. VEGF guides angiogenic sprouting utilizing endothelial tip cell filopodia. J Cell Biol 2003;161(6):1163-77
29. Gogat K, Le Gat L, Van Den Berghe L, et al. VEGF and KDR gene expression during human embryonic and fetal eye development. Invest Ophthalmol Vis Sci 2004;45:7-14
30. Safran M, Kaelin WJ Jr. HIF hydroxylation and the mammalian oxygen-sensing pathway. J Clin Invest 2003;111:779-83
31. Bhisitkul RB. Vascular endothelial growth factor biology: Clinical implications for ocular treatments. Br J Ophthalmol 2006;90(12):1542-7
32. Blaauwgeers HG, Holtkamp GM, Rutten H, et al. Polarized vascular endothelial growth factor secretion by human retinal pigment epithelium and localization of vascular endothelial growth factor receptors on the inner choriocapillaris. Evidence for a trophic paracrine relation. Am J Pathol 1999;155:421-8
33. Kim I, Ryan AM, Rohan R, et al. Constitutive expression of VEGF, VEGFR-1, and VEGFR-2 in normal eyes. Invest Ophthalmol Vis Sci 1999;40:2115-21
34. Wu KK, Thiagarajan P. Role of endothelium in thrombosis and hemostasis. Annu Rev Med 1996;47:315-31
35. Winn R, Harlan J. The role of endothelial cell apoptosis in inflammatory and immune diseases. J Thromb Haemost 2005;3:1815-24
36. Hood JD, Meininger CJ, Ziche M, et al. VEGF upregulates ecNOS message, protein, and NO production in human endothelial cells. Am J Physiol 1998;274(3 part 2):H1054-
37. Dincer M, Altundag K. Angiotensin-converting enzyme inhibitors for bevacizumab-induced hypertension. Ann Pharmacother 2006;40(12):2278
38. Sane DC, Anton L, Brosnihan KP. Angiogenic growth factors and hypertension. Angiogenesis 2004;7:193-201
39. Gordon MS, Cunningham D. Managing patients treated with bevacizumab combination therapy. Oncology 2005;69:S25-33
40. Mourad JJ, des Guetz G, Debbabi H, et al. Blood pressure rise following angiogenesis inhibition by bevacizumab. A crucial role for microcirculation. Ann Oncol 2008;19:927-34
41. Mete A, Saygili O, Mete A, et al. Effects of intravitreal bevacizumab (Avastin) therapy on retrobulbar blood flow parameters in patients with neovascular age-related macular degeneration. J Clin Ultrasound 2010;38(2):66-70
42. von Hanno T, Kinge B, Fossen K. Retinal artery occlusion following intravitreal anti-VEGF therapy. Acta Ophthalmol 2010;88(2):263-6
43. Eremina V, Jefferson JA, Kowalewska J, et al. VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med 2008;358:1129-36
44. Ferrara N, Davis-Smyth T. The biology of vascular endothelial growth factor. Endocr Rev 1997;18:4-25
45. Gerber HP, Dixit V, Ferrara N. Vascular endothelial growth factor induces expression of the antiapoptotic proteins Bcl-2 and A1 in vascular endothelial cells. J Biol Chem 1998;273:13313-16
46. Gerber HP, McMurtrey A, Kowalski J, et al. Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3'-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation. J Biol Chem 1998;273(46):30336-43
47. Kilickap S, Abali H, Celik I. Bevacizumab, bleeding, thrombosis, and warfarin. J Clin Oncol 2003;15:21(18):3542
48. Zachary I. Signaling mechanisms mediating vascular protective actions of vascular endothelial growth factor. Am J Physiol Cell Physiol 2001;280(6):C1375-86
49. Scappaticci FA, Skillings JR, Holden SN, et al. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst 2007;99:1232-9
50. Asahara T, Bauters C, Pastore C, et al. Local delivery of vascular endothelial growth factor accelerates reendothelialization and attenuates intimal hyperplasia in balloon-injured rat carotid artery. Circulation 1995;91:2793-801
51. Gennaro G, Menard C, Michaud SE, et al. Age-dependent impairment of reendothelialization after arterial injury: Role of vascular endothelial growth factor. Circulation 2003;107:230-3
52. Hutter R, Carrick FE, Valdiviezo C, et al. Vascular endothelial growth factor regulates reendothelialization and neointima formation in a mouse model of arterial injury. Circulation 2004;110(16):2430-5
53. Tam BY, Wei K, Rudge JS, et al. VEGF modulates erythropoiesis through regulation of adult hepatic erythropoietin synthesis. Nat Med 2006;12:793-800
54. Meyer T, Robles-Carrillo L, Robson T, et al. Bevacizumab immune complexes activate platelets and induce thrombosis in FCGR2A transgenic mice. J Thromb Haemost 2009;7(1):171-81
55. Weltermann A, Wolzt M, Petersmann K, et al. Large amounts of vascular endothelial growth factor at the site of hemostatic plug formation in vivo. Arterioscler Thromb Vasc Biol 1999;19:1757-60
56. Grisanti S, Ziemssen F. Bevacizumab: Off-label use in ophthalmology. Indian J Ophthalmol 2007;55(6):417-20
57. Brown DM, Heier JS, Ciulla T, et al; CLEAR-IT 2 Investigators. Primary endpoint results of a phase II study of vascular endothelial growth factor trap-eye in wet age-related macular degeneration. Ophthalmology 2011;118:1089-97
58. Ng EW, Shima DT, Calias P, et al. Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease. Nat Rev Drug Discov 2006;5(2):123-32
59. Lee JH, Canny MD, De Erkenez A, et al. A therapeutic aptamer inhibits angiogenesis by specifically targeting the heparin binding domain of VEGF165. Proc Natl Acad Sci USA 2005;102:18902-7
60. Waheed NK, Miller JW. Aptamers, intramers, and vascular endothelial growth factor. Int Ophthalmol Clin 2004;44:11-22
61. Ishida S, Usui T, Yamashiro K, et al. VEGF 164-mediated inflammation is required for pathological, but not physiological, ischemia-induced retinal neovascularisation. J Exp Med 2003;198:483-9
62. Ishida S, Usui T, Yamashiro K, et al. VEGF 164 is proinflammatory in the diabetic retina. Invest Ophthalmol Vis Sci 2003;44:2155-62
63. Ng E, Nishijima K, Robinson GS, et al. VEGF has both direct and indirect neuroprotective effects in ischemic retina. Invest Ophthalmol Vis Sci 2006;47:4829
64. Presta LG, Chen H, O'Connor SJ, et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 1997;57:4593-9
65. Ferrara N, Hillan KJ, Gerber HP, et al. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 2004;3(5):391-400
66. Rosenfeld PJ, Moshfeghi AA, Puliafito CA. Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging 2005;36:331-5
67. Rosenfeld PJ, Brown DM, Heier JS, et al MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;355:1419-31
68. Brown DM, Kaiser PK, Michels M, et al. ANCHOR Study Group. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006;355:1432-44
69. Lucentis [package insert]. Genentech, Inc; San Francisco, Calif: 2006
70. van Wijngaarden P, Coster DJ, Williams KA. Inhibitors of ocular neovascularization: Promises and potential problems. JAMA 2005;293:1509-13
71. Holash J, Davis S, Papadopoulos N, et al. VEGF-Trap: A VEGF blocker with potent antitumor effects. Proc Natl Acad Sci USA 2002;99:11393e8
72. Saishin Y, Saishin Y, Takahashi K, et al. VEGFTrapR1R2 suppresses choroidal neovascularization and VEGF-induced breakdown of the blood-retinal barrier. J Cell Physiol 2003;195:241e8
73. Stewart MW. Aflibercept (VEGF-TRAP): The next anti-VEGF drug. Inflamm Allergy Drug Targets 2011;10:497-508
74. Miyake T, Sawada O, Kakinoki M, et al. Pharmacokinetics of bevacizumab and its effect on vascular endothelial growth factor after intravitreal injection of bevacizumab in macaque eyes. IOVS 2010;51:1606-8
75. Gaudreault J, Fei D, Rusit J, et al. Preclinical pharmacokinetics of ranibizumab (rhuFabV2) after a single intravitreal administration. Invest Ophthalmol Vis Sci 2005;46:726-33
76. Bakri SJ, Snyder MR, Reid JM, et al. Pharmacokinetics of intravitreal bevacizumab (Avastin). Ophthalmology 2007;114:855-9
77. Bakri SJ, Snyder MR, Reid JM, et al. Pharmacokinetics of intravitreal ranibizumab (Lucentis). Ophthalmology 2007;114:2179-82
78. Iyer MN, He F, Wensel TG, et al. Clearance of intravitreal moxifloxacin. Invest Ophthalmol Vis Sci 2006;47:317-19
79. Fauser S, Kalbacher H, Alteheld N, et al. Pharmacokinetics and safety of intravitreally delivered etanercept. Graefes Arch Clin Exp Ophthalmol 2004;242:582-6
80. Scholes GN, O'Brien WJ, Abrams GW, Kubicek MF. Clearance of triamcinolone from vitreous. Arch Ophthalmol 1985;103:1567-9
81. Krohne TU, Eter N, Holz FG, et al. Intraocular pharmacokinetics of bevacizumab after a single intravitreal injection in humans. Am J Ophthalmol 2008;146(4):508-12
82. Matsuyama K, Ogata N, Matsuoka M, et al. Plasma levels of vascular endothelial growth factor and pigment epithelium-derived factor before and after intravitreal injection of bevacizumab. Br J Ophthalmol 2010;94(9):1215-18
83. Csaky K, Do DV. Safety implications of vascular endothelial growth factor blockade for subjects receiving intravitreal anti-vascular endothelial growth factor therapies. Am J Ophthalmol 2009;148:647-56
84. Zimmer E, Christian BJ, Miller PE, et al. Safety evaluation of intravitreal administration of VEGF Trap in cynomolgus monkeys for 13 weeks. Invest Ophthalmol Vis Sci 2006;47:E-abstract 1751
85. Nguyen QD, Shah SM, Browning DJ, et al. A phase I study of intravitreal vascular endothelial growth factor trap-eye in patients with neovascular age-related macular degeneration. Ophthalmology 2009;116:2141-8
86. Do DV, Nguyen QD, Browning DJ, et al. Results of a phase I study of intravitreal VEGF Trap in subjects with diabetic macular edema: The CLEAR-IT DME Study. IOVS 2007;48:ARVO E-abstract 1430/B486
87. Drolet DW, Nelson J, Tucker CE, et al. Pharmacokinetics and safety of an anti-vascular endothelial growth factor aptamer (NX1838) following injection into the vitreous humor of rhesus monkeys. Pharm Res 2000;17:1503-10
88. Gaudreault J, Fei D, Rusit J, et al. Preclinical pharmacokinetics of Ranibizumab (rhuFabV2) after a single intravitreal administration. Invest Ophthalmol Vis Sci 2005;46:726-33
89. Cunha-Vaz J, Faria de Abreu JR, Campos AJ. Early breakdown of the blood-retinal barrier in diabetes. Br J Ophthalmol 1975;59:649-56
90. Vinores SA, Derevkanik NL, Ozaki H, et al. Cellular mechanisms of blood-retinal barrier dysfunction in macular edema. Doc Ophthalmol 1999;97:217-28
91. Martin DF, Maguire MG, Ying GS, et al CATT Research Group. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 2011;364:1897-908
92. Martin DF, Maguire MG, Fine SL, et al CATT Research Group Writing Committee. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: 2012;119:1388-98
93. Gragoudas ES, Adamis AP, Cunningham ET Jr, et al VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group. VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 2004;351:2805-16
94. Macugen AMD Study Group, Apte RS, Modi M, Masonson H, et al. Pegaptanib 1-year systemic safety results from a safety-pharmacokinetic trial in patients with neovascular age-related macular degeneration. Ophthalmology 2007;114:1702-12
95. Chakravarthy U, Adamis AP, Cunningham ET Jr, et al. Year 2 efficacy results of 2 randomized controlled clinical trials of pegaptanib for neovascular age-related macular degeneration. Ophthalmology 2006;113:1508-25
96. Boyer DS, Antoszyk AN, Awh CC, et al. MARINA Study Group. Subgroup analysis of the MARINA study of ranibizumab in neovascular age-related macular degeneration. phthalmology 2007;114:246-52
97. Kaiser PK, Blodi BA, Shapiro H, et al. MARINA Study Group. Angiographic and optical coherence tomographic results of the MARINA study of ranibizumab in neovascular age-related macular degeneration. Ophthalmology 2007;114:1868-75
98. Kaiser PK, Brown DM, Zhang K, et al. Ranibizumab for predominantly classic neovascular age-related macular degeneration: Subgroup analysis of first-year ANCHOR results. Am J Ophthalmol 2007;144:850-7
99. Abraham P, Yue H, Wilson L. Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: Pier study year 2. Am J Ophthalmol 2010;150(3):315-24
100. Antoszyk AN, Tuomi L, Chung CY, et al. FOCUS Study Group. Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration (FOCUS): year 2 results. Am J Ophthalmol 2008;145(5):862-74
101. Boyer DS, Chung CY, Tuomi LA. A safety overview of ranibizumab in patients with wet AMD: Anchor, MARINA, PIER, and SAILOR. Presented at the Annual Meeting of the American Academy of Ophthalmology; 8 - 11 November; Atlanta, Georgia; 2008
102. Ciulla TA, Rosenfeld PJ. Antivascular endothelial growth factor therapy for neovascular age-related macular degeneration. Curr Opin Ophthalmol 2009;20:158-65
103. Mitchell P, Korobelnik JF, Lanzetta P, et al. Ranibizumab (Lucentis) in neovascular age-related macular degeneration: Evidence from clinical trials. Br J Ophthalmol 2010;94(1):2-13
104. Chong NV. Should avastin be used to treat age-related macular degeneration in the NHS? No. Eye (Lond) 2009;23:1250-3
105. Ueta T, Yanagi Y, Tamaki Y, Yamaguchi T. Cerebrovascular accidents in ranibizumab. Ophthalmology 2009;116:362
106. Bashshur ZF, Schakal A, Hamam RN, et al. Intravitreal bevacizumab vs verteporfin photodynamic therapy for neovascular age-related macular degeneration. Arch Ophthalmol 2007;125:1357-61
107. Avery RL, Pieramici DJ, Rabena MD, et al. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology 2006;113:363-72
108. Wu L, Martinez Castellanos MA, Quiroz-Mercado H, et al. for the Pan American Collaborative Retina Group. Twelve-month safety of intravitreal injections of bevacizumab (Avastin1): Results of the Pan-American Collaborative Retina Study Group (PACORES). Graefes Arch Clin Exp Ophthalmol 2008;246:81-7
109. Rosenfeld PJ, Schwartz SD, Blumenkranz MS, et al. Maximum tolerated dose of a humanized anti-vascular endothelial growth factor antibody fragment for treating neovascular age-related macular degeneration. Ophthalmology 2005;112:1048-53
110. Curtis LH, Hammill BG, Schulman KA, et al. Risks of mortality, myocardial infarction, bleeding, and stroke associated with therapies for age-related macular degeneration. Arch Ophthalmol 2010;128(10):1273-9
111. Available from: Http://www.clinicaltrials. gov/ct2/show/NCT00559715? term=VIBERA+Study&rank=1
112. Available from: Http://newsroom. regeneron.com/releasedetail.cfm 113. Nguyen QD, Shah SM, Hafiz G, et al. CLEAR-AMD 1 Study Group. A phase 1 trial of intravenously administered vascular endothelial growth factor trap for treatment in patients with choroidal neovascularization due to age-related macular degeneration. Ophthalmology 2006;113:1522-32
113. Nguyen QD, Shah SM, Browning DJ, et al. A phase 1 study of intravitreal vascular endothelial growth factor Trap-Eye in patients with neovascular age-related macular degeneration. Ophthalmology 2009;116:2141-8
114. Heier JS, Boyer D, Nguyen QD, et al. The 1-year results of CLEAR-IT 2, a phase 2 study of vascular endothelial growth trap-eye dosed as-needed after 12-week fixed dosing. Ophthalmology 2011;118:1098e106
115. Heier JS. VEGF Trap-Eye Phase III Trial Results. VIEW 1 results. Paper presented at: Angiogenesis, Exudation, and Degeneration 2011; 12 February 2011; Miami 117. Schmidt-Erfurth U. VEGF Trap-Eye Phase III Trial Results. VIEW 2 results. Paper presented at: Angiogenesis, Exudation, and Degeneration 2011; 12 February 2011; Miami 118. Campa C, Harding SP. Anti-VEGF compounds in the treatment of neovascular age related macular degeneration. Curr Drug Targets 2011;12:173-81
116. Tunon J, Ruiz-Moreno JM, Martin-Ventura JL, et al. Cardiovascular risk and antiangiogenic therapy for age-related macular degeneration. Surv Ophthalmol 2009;54:339-48
117. Stewart MW. The expanding role of vascular endothelial growth factor inhibitors in ophthalmology. Mayo Clin Proc 2012;87:77-88
118. Rosenstein JM, Krum JM. New roles for VEGF in nervous tissue beyond blood vessels. Exp Neurol 2004;187:246-53
119. Jin K, Zhu Y, Sun Y, et al. Vascular endothelial growth factor (VEGF) stimulates neurogenesis in vitro and in vivo. Proc Natl Acad Sci USA 2002;99:11946-50
120. Barleon B, Sozzani S, Zhou D, et al. Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1. Blood 1996;87:3336-43
121. Costagliola C, Romano MR, Rinaldi M, et al. Low fluence rate photodynamic therapy combined with intravitreal bevacizumab for neovascular age-related macular degeneration. Br J Ophthalmol 2010;94:180-4